Growth hormone trial aims to boost muscle in Prader-Willi patients
NCT ID NCT04697381
First seen Jan 16, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This completed Phase 3 study tested somatropin, a synthetic growth hormone, in 33 Japanese children and adults with Prader-Willi syndrome. The goal was to see if it safely improves body composition by increasing lean body mass and reducing fat. Participants were divided into three groups based on age and prior growth hormone use, and changes were measured over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRADER-WILLI SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dokkyo Medical University Saitama Medical Center
Koshigaya, Saitama, 343-8555, Japan
-
Hamamatsu University Hospital
Hamamatsu, Shizuoka, 431-3192, Japan
-
Kanagawa Children's Medical Center
Yokohama, Kanagawa, 232-8555, Japan
-
National Center for Child Health and Development
Setagaya-ku, Tokyo, 157-8535, Japan
-
Osaka Women's and Children's Hospital
Izumi, Osaka, 594-1101, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
somatropin (a synthetic growth hormone)
What this could lead to
If successful, this could confirm somatropin as a safe and effective way to improve body composition (more lean muscle, less fat) in people with Prader-Willi syndrome.
What could go wrong
This is a small, open-label study (no placebo group) in Japanese participants only, so results may not apply broadly. Growth hormone therapy has known side effects like joint pain and swelling.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.